Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Biochemistry and Biophysics Reports|August 30, 2021
Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life spanYuichi Takashi, Shun Sawatsubashi, Itsuro Endo, et al.
JACC. Advances|June 28, 2024
FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation AnalysisNaoko Hidaka, Kosuke Inoue, Hajime Kato, et al.
Medicine|October 31, 2020
Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgeryYusuke Morinaga, Ichiro Abe, Kouhei Nii, et al.
Endocrine Journal|July 26, 2021
Comparison and commutability study between standardized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in bloodTetsuo Nishikawa, Fumitoshi Satoh, Yuichi Takashi, et al.
Plos One|May 4, 2019
Circulating osteocalcin as a bone-derived hormone is inversely correlated with body fat in patients with type 1 diabetesYuichi Takashi, Masashi Ishizu, Hiroyasu Mori, et al.
Heliyon|November 18, 2020
Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat dietTsuyoshi Horikawa, Takako Kawanami, Yuriko Hamaguchi, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 18, 2019
Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylationYuichi Takashi, Hidetaka Kosako, Shun Sawatsubashi, et al.
Medicine|November 26, 2019
Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parametersIchiro Abe, Kentaro Ochi, Yuichi Takashi, et al.
Journal of Diabetes Investigation|May 7, 2025
Liver function effects of SGLT2 inhibitor and GLP-1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)Daisuke Tsuriya, Kazuo Kobayashi, Kei Takeshita, et al.
The Tokai Journal of Experimental and Clinical Medicine|March 19, 2025
Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP StudyYoshimi Muta, Kazuo Kobayashi, Masao Toyoda, et al.
Pageof 6